search
Back to results

Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina

Primary Purpose

Angina Pectoris, Diabetes Mellitus, Type 2

Status
Withdrawn
Phase
Phase 4
Locations
United Kingdom
Study Type
Interventional
Intervention
Rosiglitazone
Gliclazide (Comparison drug)
Sponsored by
University of Glasgow
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Angina Pectoris focused on measuring Angina, Ischaemic heart disease, Diabetes

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Chronic stable angina with ongoing symptoms. (The treatment goal being an improvement in symptoms) Participants will have uncontrolled diabetes (Hba1c>7.5) on metformin monotherapy (so the diabetes is not over treated) Participants will be diabetic for less than 8 years. Exclusion Criteria: Renal impairment (creatinine >130mmol/l) Hepatic Impairment (ALT>70U/l, AST>80U/l) Any clinical signs of heart failure Physical disability precluding treadmill exercise tolerance testing Abnormal resting ECG (left or right bundle-branch block, left or right ventricular hypertrophy, ventricular preexcitation, Q-wave myocardial infarction, digitalis therapy) Women of childbearing potential Women who are breastfeeding

Sites / Locations

  • Cardiology Department, Glasgow Royal Infirmary

Outcomes

Primary Outcome Measures

Angina status at 3 months

Secondary Outcome Measures

Pulse wave velocity at 3 months
Small vessel function at 3 months
Haemostatic markers at 3 months
Biochemical markers of inflammation at 3 months

Full Information

First Posted
September 21, 2005
Last Updated
September 7, 2006
Sponsor
University of Glasgow
Collaborators
GlaxoSmithKline
search

1. Study Identification

Unique Protocol Identification Number
NCT00225342
Brief Title
Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina
Official Title
Effects of Rosiglitazone and Sulphonylureas on Ischaemic Burden, Blood Pressure and Novel Risk Markers Inclusive of Vascular Function in Patients With Chronic Stable Angina and Type 2 Diabetes Mellitus: A Randomised, Double-Blinded Study.
Study Type
Interventional

2. Study Status

Record Verification Date
September 2005
Overall Recruitment Status
Withdrawn
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
University of Glasgow
Collaborators
GlaxoSmithKline

4. Oversight

5. Study Description

Brief Summary
The principle objective of the trial is to compare rosiglitazone to gliclazide in patients with type 2 diabetes mellitus and chronic stable angina to see how the subjects' angina status changes. Angina status will be measured via exercise tolerance testing, 24-hour ECG testing and angina quality of life questionnaire.
Detailed Description
Ischaemic heart disease is one of the main complications of type 2 diabetes mellitus, both in terms of morbidity and mortality. Reducing plasma glucose with hypoglycaemic agents has not been shown to improve cardiovascular mortality or morbidity. Chronic stable angina is a common problem in patients with type 2 diabetes mellitus. We postulate that in subjects with uncontrolled type 2 diabetes mellitus (Hba1c >7.5%), on metformin therapy, and chronic stable angina that the addition of the insulin sensitiser, rosiglitazone to control their diabetes will improve their angina when compared to the addition of the hypoglycaemic agent gliclazide. This hypothesis is based on the fact that insulin resistance is an upstream mechanism common to both conditions. We will randomise such patients to 3 months therapy of rosiglitazone or gliclazide for 3 months, comparing angina status before and after by way of full Bruce protocol exercise testing, 24 hour ST segment analysis and angina questionnaire.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Angina Pectoris, Diabetes Mellitus, Type 2
Keywords
Angina, Ischaemic heart disease, Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
60 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Rosiglitazone
Intervention Type
Drug
Intervention Name(s)
Gliclazide (Comparison drug)
Primary Outcome Measure Information:
Title
Angina status at 3 months
Secondary Outcome Measure Information:
Title
Pulse wave velocity at 3 months
Title
Small vessel function at 3 months
Title
Haemostatic markers at 3 months
Title
Biochemical markers of inflammation at 3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Chronic stable angina with ongoing symptoms. (The treatment goal being an improvement in symptoms) Participants will have uncontrolled diabetes (Hba1c>7.5) on metformin monotherapy (so the diabetes is not over treated) Participants will be diabetic for less than 8 years. Exclusion Criteria: Renal impairment (creatinine >130mmol/l) Hepatic Impairment (ALT>70U/l, AST>80U/l) Any clinical signs of heart failure Physical disability precluding treadmill exercise tolerance testing Abnormal resting ECG (left or right bundle-branch block, left or right ventricular hypertrophy, ventricular preexcitation, Q-wave myocardial infarction, digitalis therapy) Women of childbearing potential Women who are breastfeeding
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Naveed Sattar, MBChB PhD
Organizational Affiliation
University of Glasgow
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Stuart M Cobbe, MBChB MD
Organizational Affiliation
University of Glasgow
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cardiology Department, Glasgow Royal Infirmary
City
Glasgow
ZIP/Postal Code
G4 0SF
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina

We'll reach out to this number within 24 hrs